AEON Biopharma announces leadership change amid growth strategy

IRVINE, Calif. - AEON Biopharma, Inc. (NYSE: AEON), a clinical-stage biopharmaceutical company, announced the resignation of its President and CEO Marc Forth, effective April 4, 2025. Forth will continue to serve on the company’s board of directors, providing strategic guidance. Jost Fischer, Chairman of the Board, will step in as interim CEO during the search for a permanent replacement.

The company, which is developing a botulinum toxin complex for various therapeutic indications, is currently progressing through a 351(k) biosimilar regulatory pathway. This process could potentially enable AEON to market its product, ABP-450, across all current and future therapeutic indications approved for BOTOX with a single FDA approval.

Fischer, who has been with AEON’s board since February 2017, acknowledged Forth’s significant contributions to the company’s growth strategy. He also expressed his commitment to advancing the ABP-450 program without interruption, emphasizing the company’s adequate cash balances to support upcoming FDA discussions in the second half of 2025.

AEON’s ABP-450, also known as prabotulinumtoxinA injection, is the same botulinum toxin complex marketed by Evolus under the name Jeuveau for cosmetic indications. It is manufactured by Daewoong in compliance with Good Manufacturing Practice and has been approved by regulatory authorities in the U.S., Canada, and Europe. AEON holds exclusive development and distribution rights for therapeutic indications of ABP-450 in various regions, including the United States and European Union.

The company has a seasoned management team with expertise in biopharmaceutical development and the commercialization of botulinum toxin products. AEON’s forward-looking statements reflect plans for future meetings with the FDA and the development of ABP-450 as a biosimilar to BOTOX.

This leadership transition news is based on a press release statement from AEON Biopharma.

In other recent news, AEON Biopharma, Inc. announced a 1-for-72 reverse stock split approved by its Board of Directors. This move aims to meet the NYSE American LLC compliance standards by elevating the company’s common stock price. The reverse stock split will take effect at the start of the trading day on February 26, 2025. Stockholders authorized this action during a Special Meeting, allowing a reverse stock split in a range of 1-for-5 to 1-for-150, with the Board finalizing the ratio at 1-for-72. The reverse stock split will not change the ownership percentage of stockholders, except for fractional shares, which will be rounded up. AEON Biopharma has filed the details of this stock split with the Securities and Exchange Commission in a Current Report on Form 8-K. This effort is part of AEON’s strategy to maintain its NYSE American listing by adhering to the exchange’s minimum share price requirements. These developments reflect AEON’s ongoing efforts to stabilize its market presence and ensure compliance with trading standards.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.